

## **ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide**

*National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy*

LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV-a significant advancement in intravenous NAD+ therapy-more widely accessible to wellness enthusiasts looking to enhance cellular health and extend their healthspan.

Available in oral and IV forms, ChromaDex's clinically proven patented ingredient, Niagen, is the most efficient, high-quality NAD+ precursor available. NAD+ is a coenzyme that powers cells and supports metabolic processes throughout the body, yet it declines with age and due to everyday stressors like sun exposure, high-fat diets, overtraining, and sedentary lifestyles-a decline linked to both age-related and other health conditions.

The IV formulations support the rapid and efficient delivery of Niagen. Outperforming NAD+ IV in the pilot clinical study, Niagen IV offered superior tolerability, a 75% shorter infusion time, and resulted in a statistically significant 20% increase in whole blood NAD+ levels three hours post-infusion, as measured by NAD+ dried blood spot tests (*MedRxiv*).

"Niagen IV is a superior solution to traditional NAD+ IV," said Rob Fried, CEO of ChromaDex. "We are pleased that reliably science based Restore Hyper Wellness recognizes these advantages and is offering Niagen IV nationwide."

Restore Hyper Wellness, known for its innovative approach to proactive health and wellness, provides access to advanced modalities, with safety and efficacy as core principles. Restore's extensive network of clinics offers clients a holistic experience designed to address their wellness goals and optimize physical health.

"We've seen firsthand how Niagen IV elevates the wellness experience for our clients, delivering enhanced cellular support compared to NAD+ IV," said Dr. Rachele Pojednic, Director of Scientific Research & Education at Restore Hyper Wellness. "Pharmaceutical-grade Niagen provides a cutting-edge option that reflects our commitment to impactful, science-driven care."

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, compounds and distributes pharmaceutical-grade Niagen for clinics, which is available as Niagen IV

exclusively for clinics, such as Restore Hyper Wellness, with medical clearance.

To learn more about Niagen IV at Restore Hyper Wellness, visit [www.restore.com](http://www.restore.com). Consumers can visit [www.niagenplus.com](http://www.niagenplus.com) to sign up for product news and updates on future clinic availability and use the store locator to find a clinic offering Niagen IV near you.

### **Forward-Looking Statements:**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to future increased availability of pharmaceutical grade Niagen, and future performance of pharmaceutical grade Niagen. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at [www.sec.gov](http://www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

### **About ChromaDex:**

ChromaDex Corp. (NASDAQ: CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD<sup>+</sup>), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD<sup>+</sup>. A vital coenzyme found in every cell of the human body, NAD<sup>+</sup> declines with age and exposure to other everyday stressors. NAD<sup>+</sup> depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen<sup>®</sup> is the active ingredient in ChromaDex's consumer products, sold as the brand Tru Niagen<sup>®</sup>, the number one healthy-aging NAD+ supplement in the United States. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at [www.truniagen.com](http://www.truniagen.com)). ChromaDex supplies pharmaceutical-grade Niagen<sup>®</sup> to U.S. FDA-registered 503B outsourcing facilities, which compound and distribute intravenous and injectable Niagen<sup>®</sup> for clinics. These pharmaceutical-grade Niagen<sup>®</sup> products, known as Niagen IV and Niagen injections, are available exclusively at clinics with a prescription ([www.niagenplus.com](http://www.niagenplus.com)).

ChromaDex's robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at [www.chromadex.com](http://www.chromadex.com), where copies of press releases, news, and financial information are regularly published.

*Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).*

### **About Restore Hyper Wellness:**

Launched in Austin, Texas in 2015, Restore is expanding the limits of personal health and performance, to help people do more of what they love through personalized, science-backed therapies. Restore delivers expert guidance and an extensive array of cutting-edge wellness therapies integrated under one roof, including Cryotherapy, Red Light Therapy, Infrared Sauna, Compression, IV Drip Therapy, Intramuscular (IM) Shots, Mild Hyperbaric Oxygen Therapy, Neveskin, Hydrafacial™, and more. With 225+ studios nationwide, Restore is the largest direct-to-consumer proactive healthcare provider.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20241107717521/en/>

### **ChromaDex Media Contact:**

Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

[kendall.knysch@chromadex.com](mailto:kendall.knysch@chromadex.com)

**ChromaDex Investor Relations Contact:**

Ben Shamsian

Lytham Partners

646-829-9701

[shamsian@lythampartners.com](mailto:shamsian@lythampartners.com)